Most MSL teams use a single engagement model across academic centers and community practices. New ZoomRx research shows that is a strategic mistake. Academic and community oncologists define a “good” MSL in fundamentally different ways.
Insights in this article are drawn from the ZoomRx Oncology Medical Engagement Perception Report 2026. Segment-level findings highlight distinct patterns in how academic and community oncologists evaluate MSL interactions.
If your MSL team is run on a single playbook across academic and community settings, half your field is being managed against the wrong success criteria. The MSLs are not failing. They are calibrated for one audience and being deployed against another. These are two different jobs that happen to share a title.
In the ZoomRx study, academic and community oncologists were asked separately what they look for in an MSL interaction. The two groups gave answers that are not variations on a theme. They are different value systems.
Academic oncologists assigned Scientific Depth the highest importance weight (20.3). They treat MSLs as scientific peers and expect substance: pre-publication data, pipeline access, a sophisticated take on the emerging landscape. If the MSL cannot hold their own on the science, the relationship does not really start.
Community oncologists ranked Responsiveness as the most important attribute (22.3 points of weight). They want practical, fast, applicable answers. They are not looking for a research partner. They are looking for someone who can help them make a decision about a real patient today, and who picks up the phone the next time they need something.
The same MSL profile that earns trust in an academic center can quietly underperform in a community practice. Same skills. Different expectations. Different verdict.
Consider a realistic but fictionalized scenario. A mid-sized oncology company audits its MSL performance and finds the team scoring strongly in academic centers, with consistent feedback on research collaboration and scientific exchange. In community practices, the same team scores below the field average, with a recurring complaint that the MSLs are difficult to reach and slow to provide practical answers.
On paper, the team’s aggregate performance looks fine. Inside the data, two stories are running in parallel. The academic side is winning. The community side is just keeping up. Aggregation hides the gap. The two signals offset each other in the average.
The fix is not retraining the MSL team. It is recognizing that the company has been running to jobs under one title, and calibrating hiring, coaching, and territory design accordingly.
“Aggregated MSL performance hides the gap. The academic signal and the community signal cancel each other out in the average.”
If your MSL team operates with a single playbook across both settings, the consequences are predictable:
This is exactly what ZoomRx's Medical Engagement Effectiveness Tracker (MET) measures. MET segments and benchmarks MSL performance by setting (academic vs community), by therapeutic area, and against the competitor set, so each operating model is evaluated against the success criteria its audience actually uses. You stop reading an average that hides the real story and start seeing where each engagement model is working and where it is not.
If academic and community performance are blended in your metrics, you will never see which half of your MSL model is really working. Get in Touch with us to see how MET segments and benchmarks performance, and to design a no-cost initial MET engagement around your priority accounts.